BIJAL DAVE: Open Payments
NPI 1770733321 · HACKETTSTOWN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,913 in 113 payments from 20 companies in 2025. Trend: 2023 $1,662 · 2024 $2,141 · 2025 $1,913
Food & beverage: $1,913
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 30 | $368 |
| Amgen Inc. | 17 | $303 |
| Corcept Therapeutics | 7 | $197 |
| AstraZeneca Pharmaceuticals LP | 9 | $193 |
| ABBVIE INC. | 18 | $177 |
| Lilly USA, LLC | 10 | $147 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $104 |
| Boston Scientific Corporation | 1 | $103 |
| Exact Sciences Corporation | 3 | $63 |
| Astellas Pharma US Inc | 3 | $50 |
Products named: Korlym, Ozempic, Repatha, MOUNJARO, JARDIANCE, WATCHMAN FLX, FARXIGA, VRAYLAR.
Industry payments across NJ — which companies pay providers there.
